-
Block T M, Lu X, Mehta A S. Treatment of chronic hepadnavirus infection in a woodchuck animal model with an inhibitor of protein folding and trafficking[J]. Nat Med, 1998, 4(): 610-614. doi: 10.1038/nm0598-610
-
Chotiyaputta W, Lok A. hepatitis B virus variants[J]. Nat Rev Gastroenterol Hepatol, 2009, 6(): 453-462. doi: 10.1038/nrgastro.2009.107
-
Delaney W E 4th, Edwards R, Colledge D. Phenylpropenamide derivatives AT-61 and AT-130 inhibit replication of wild-type and lamivudine-resistant strains of hepatitis B virus in vitro[J]. Antimicrob Agents Chemother, 2002, 46(): 3057-3060. doi: 10.1128/AAC.46.9.3057-3060.2002
-
Deng Q, Zhai J W, Michel M L. Identification and characterization of peptides that interact with hepatitis B virus via the putative receptor binding site[J]. J Virol, 2007, 81(): 4244-4254. doi: 10.1128/JVI.01270-06
-
Deres K, Schroder C H, Paessens A. Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids[J]. Science, 2003, 299(): 893-896. doi: 10.1126/science.1077215
-
Dienstag J L. Hepatitis B virus infection[J]. N Engl J Med, 2008, 359(): 1486-1500. doi: 10.1056/NEJMra0801644
-
Ganem D, Prince A M. Hepatitis B virus infection-natural history and clinical consequences[J]. N Engl J Med, 2004, 350(): 1118-1129. doi: 10.1056/NEJMra031087
-
Glebe D, Urban S, Knoop E V. Mapping of the hepatitis B virus attachment site by use of infection-inhibiting preS1 lipopeptides and tupaia hepatocytes[J]. Gastroenterology, 2005, 129(): 234-245. doi: 10.1053/j.gastro.2005.03.090
-
Gripon P, Cannie I, Urban S. Efficient inhibition of hepatitis B virus infection by acylated peptides derived from the large viral surface protein[J]. J Virol, 2005, 79(): 1613-1622. doi: 10.1128/JVI.79.3.1613-1622.2005
-
King R W, Ladner S K, Miller T J. Inhibition of human hepatitis B virus replication by AT-61, a phenylpropenamide derivative, alone and in combination with (-)β-L-2', 3'-dideoxy-3'-thiacytidine[J]. Antimicrob Agents Chemother, 1998, 42(): 3179-3186.
-
Lampertico P., Viganò M, Manenti E. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients[J]. Gastroenterology, 2007, 133(): 1445-1451. doi: 10.1053/j.gastro.2007.08.079
-
Lazar C, Durantel D, Macovei A. Treatment of hepatitis B virus-infected cells with alpha-glucosidase inhibitors results in production of virions with altered molecular composition and infectivity[J]. Antiviral Res, 2007, 76(): 30-37. doi: 10.1016/j.antiviral.2007.04.004
-
Lucifora J, Durantel D, Testoni B. Control of hepatitis B virus replication by innate response of HepaRG cells[J]. Hepatology, 2010, 51(): 63-72. doi: 10.1002/hep.23230
-
Mancini-Bourgine M, Fontaine H, Bréchot C. Immunogenicity of a hepatitis B DNA vaccine administered to chronic HBV carriers[J]. Vaccine, 2006, 24(): 4482-4489. doi: 10.1016/j.vaccine.2005.08.013
-
Mehta A, CarrouȦe S, Conyers B. Inhibition of hepatitis B virus DNA replication by imino sugars without the inhibition of the DNA polymerase: therapeutic implications[J]. Hepatology, 2001, 33(): 1488-1495. doi: 10.1053/jhep.2001.25103
-
Perrillo R. Benefits and risks of interferon therapy for hepatitis B[J]. Hepatology, 2009, 49(): S103-111. doi: 10.1002/hep.v49.5s
-
Petersen J, Dandri M, Mier W. Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein[J]. Nat Biotechnol, 2008, 26(): 335-341. doi: 10.1038/nbt1389
-
Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection[J]. Nature Rev Immunol, , 5(): 215-229. doi: 10.1038/nri1573
-
Riordan S M, Skinner N, Kurtovic J. Reduced expression of toll-like receptor 2 on peripheral monocytes in patients with chronic hepatitis B[J]. Clin Vaccine Immunol, 2006, 13(): 972-974. doi: 10.1128/CVI.00396-05
-
Seeger C, Mason W S. 2005. Hepatitis B virus biology. Microbiol Mol Biol Rev, 2000, 64: 51-68.
-
Shepard C W, Simard E P, Finelli L. Hepatitis B virus infection: epidemiology and vaccination[J]. Epidemiol Rev, 2006, 28(): 112-125. doi: 10.1093/epirev/mxj009
-
Thompson A J, Colledge D, Rodgers S. Stimulation of the interleukin-1 receptor and Toll-like receptor 2 inhibits hepatitis B virus replication in hepatoma cell lines in vitro[J]. Antivir Ther, 2009, 14(): 797-808. doi: 10.3851/IMP1294
-
Vincent I E, Lucifora J, Durantel D. Inhibitory effect of the combination of CpG-induced cytokines with lamivudine against hepatitis B virus replication in vitro[J]. Antivir Ther, 2009, 14(): 131-135.
-
Weber O, Schlemmer K H, Hartmann E. Inhibition of human hepatitis B virus (HBV) by a novel non-nucleosidic compound in a transgenic mouse model[J]. Antiviral Res, 2002, 54(): 69-78. doi: 10.1016/S0166-3542(01)00216-9
-
Xu D Z, Zhao K, Guo L M. A randomized controlled phase òb trial of antigen-antibody immunogenic complex therapeutic vaccine in chronic hepatitis B patients[J]. PLoS One, 2008, (3): e2565-.
-
Yao X, Zheng B, Zhou J. Therapeutic effect of hepatitis B surface antigen-antibody complex is associated with cytolytic and non-cytolytic immune responses in hepatitis B patients[J]. Vaccine, 2007, 25(): 1771-1779. doi: 10.1016/j.vaccine.2006.11.019
-
Zimmerman K A, Fischer K P, Joyce M A. Zinc finger proteins designed to specifically target duck hepatitis B virus covalently closed circular DNA inhibit viral transcription in tissue culture[J]. J Virol, 2008, 82(): 8013-8021. doi: 10.1128/JVI.00366-08